Download eisai to present new research on oncology products and pipeline at

May 24, 2016
Eisai Co., Ltd.
No. 16-34
EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY
PRODUCTS AND PIPELINE AT 52ND ASCO ANNUAL MEETING
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of
abstracts highlighting new study results on Halaven® (eribulin mesylate; halichondrin class
microtubule dynamics inhibitor, “eribulin”) and Lenvima® (lenvatinib mesylate; selective inhibitor
of receptor tyrosine kinases (RTKs) with a novel binding mode, “lenvatinib”) will be presented
during the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking
place in Chicago, the United States, from June 3 to 7, 2016.
Poster presentations for this year’s ASCO meeting include a presentation highlighting the results
of a Phase I clinical study of eribulin liposomal formulation in solid tumors. Presentations for
lenvatinib include updated results from the SELECT study regarding response to lenvatinib
treatment in patients with radioiodine-refractory differentiated thyroid cancer as well as final
analysis results of a Phase II study of lenvatinib in patients with differentiated, medullary, and
anaplastic thyroid cancer.
Eisai positions oncology as a key franchise area. The company will continue to create innovation
in the development of new drugs based on cutting-edge cancer research, and in doing so seeks
to make further contributions to address the diversified needs of, and increase the benefits
provided to, patients and their families as well as healthcare providers.
Major Poster Presentations:
Product
Abstract title and scheduled presentation date and time (local time)
Eribulin
Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two
(Halaven)
administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid
Abstract No: 2524
Poster Presentation | June 5 (Sun), 08:00-11:30
Eribulin
Evaluation of quality of life at progression in patients with soft tissue sarcoma.
tumors.
(Halaven)
Abstract No: 11015
Poster Presentation | June 6 (Mon), 08:00-11:30
Eribulin
Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label,
(Halaven)
randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and
Abstract No: 11037
Poster Presentation | June 6 (Mon), 08:00-11:30
leiomyosarcoma (LMS).
(continued on following page)
Lenvatinib
Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN),
(Lenvima)
everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC).
Abstract No: 4553
Poster Presentation | June 6 (Mon), 13:00-16:30
Lenvatinib
Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid
(Lenvima)
cancer: Final analysis results.
Abstract No: 6088
Poster Presentation | June 4 (Sat), 13:00-16:30
Lenvatinib
Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid
(Lenvima)
cancer (RR-DTC): Updated results from SELECT.
Abstract No: 6089
Poster Presentation | June 4 (Sat), 13:00-16:30
(Note) SELECT Study: Study of E7080 “LEnvatinib” in Differentiated Cancer of the Thyroid
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120